High Dose Risankizumab for Psoriasis

Completed · Phase 2

Conditions studied: Psoriasis

In brief

This pilot study explores higher than standard doses of risankizumab for plaque psoriasis, to see effects on resident memory T cells and skin clearance.

Key facts

Study ID

NCT05283135

Run by

Oregon Medical Research Center

People needed

20

Starts

2022-03-01

Expected to finish

2024-07-10

Last updated by the study team

2025-10-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has provided written consent
• Subject has the ability to comply with all study visits and procedures
• Subject is at least 18 years of age
• Subject has chronic stable plaque psoriasis for at least 6 months and with a severity of BSA greater than or equal to 10 and PASI greater than or equal to 12
• Female subjects of child-bearing potential must have a negative urine test at screening and baseline. Female subjects must be either postmenopausal, or permanently surgically sterile, or for women of child-bearing potential practicing at least one form of birth control

You may not qualify if…

• Breastfeeding or pregnant women, or women who plan to become pregnant during study period
• Participation in any other clinical trial
• Active infection with HIV, hepatitis B virus, or hepatitis C virus
• Active infection with tuberculosis or untreated latent tuberculosis
• History of known active cancer, other than non-melanoma skin cancer or cervical carcinoma in situ, in the past 3 years
• History of drug or alcohol abuse in the past 6 months, as per investigator's assessment
• History of suicidal ideation or attempts in the past 6 months
• Presence of any concurrent illness, which in the opinion of the investigator, would place the patient at unnecessary safety risk during the trial or interfere with completion of the trial
• Treatment with topical medications for psoriasis in the past 2 weeks
• Treatment with oral medications for psoriasis in the past 4 weeks
• Phototherapy for psoriasis in the past 4 weeks
• Any prior treatment with Risankizumab
• Treatment with biologic medications for psoriasis (other than Risankizumab) in the past 4 months

Where it is running

• Oregon Medical Research Center — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.